<DOC>
	<DOCNO>NCT01600482</DOCNO>
	<brief_summary>The objective CELT ACD® Vascular Closure Device study evaluate safety effectiveness CELT ACD® device achieve hemostasis common femoral artery access site patient anticoagulation undergo percutaneous coronary intervention ( PCI ) procedure use either 6F 7F procedural sheath .</brief_summary>
	<brief_title>Clinical Investigation Safety Efficacy Study CELT ACD Arterial Closure Device</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<criteria>1 . Over 18 year age . 2 . Each patient , guardian legal representative , willing give inform consent . 3 . Clinically indicated intraarterial procedure involve access common femoral artery conduct access sheath size 6F 7F inclusive . 1 . Patients know allergy material use device . 2 . Severe acute noncardiac systemic disease terminal illness life expectancy le one year . 3 . Evidence systemic bacterial cutaneous infection , include groin infection . 4 . Patients suffer definitive potential coagulopathy platelet count &lt; 100,000./µl 5 . Use systemic thrombolytic agent within 24 hour prior catheterisation procedure cause concentration fibrinogen &lt; 100 mg/dl postthrombolytic fibrinogen ( case thrombolysis within 24 hour intraprocedural ) measure . 6 . Patients introducer sheath small 6F great 7F use . 7 . Currently participate another investigational device drug study . 8 . Patients severe claudication , iliac femoral artery diameter stenosis great 50 % , previous bypass surgery stent placement vicinity access site . 9 . If puncture site via vascular graft . 10 . If palpable haematoma observe procedure . 11 . Patients indication puncture make profunda femorals artery superficial femoral artery , adjacent bifurcation . 12 . Patients common femoral artery lumen diameter less 5 mm . 13 . Patients amputation access site limb . 14 . Patients undergone percutaneous procedure use vascular closure device hemostasis within previous 30 day use manual/mechanical pressure hemostasis within prior 30 day leg . 15 . Patients systolic blood pressure read 90 mmHg . 16 . Patients active haematoma , arteriovenous fistula , pseudoaneurysm . 17 . Patients superficial artery depth skin artery surface access site le 4 mm . 18 . Morbidly obese patient ( Body Mass Index &gt; 35kg/m2 ) . 19 . Patients stent less equal 1 cm puncture site would interfere placement device implant . 20 . Patient know suspect pregnant , lactate . 21 . Patients antegrade puncture . 22 . Patients difficulty obtain vascular access result multiple arterial puncture and/or posterior arterial wall puncture . 23 . Patients undergone prior recent use intraaortic balloon pump arterial access site . 24 . Patients uncontrolled hypertension ( BP great equal 180/110mmHg ) time vascular closure 25 . Patients acute STelevation myocardial infarction less equal 48hours catheterization procedure . 26 . Patients cardiogenic shock ( hemodynamic instability require intravenous medication mechanical support ) experience immediately postcatherization . 27 . Patients unable ambulate baseline . 28 . Patients know require extend hospitalization ( e.g . patient undergoing cardiac surgery ) . 29 . Patient already participate trial . 30 . Patient unavailable follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hemostasis .</keyword>
	<keyword>Percutaneous coronary intervention .</keyword>
	<keyword>Closure Device</keyword>
</DOC>